Choong Ang Vaccine Laboratories Co., Ltd.
1476-37 Yuseong-daero, Yuseong-gu, Deajeon, Republic of KoreaTelephone_ +82-42-863-9322
www.cavaclab.com
Choong Ang Vaccine Laboratories Co., Ltd.
Chong Ang Vaccine Laboratories Co., Ltd.
1476-37 Yuseong-daero, Yuseong-gu, Deajeon, Republic of KoreaTelephone_ +82-42-870-0545
www.cavaclab.com
Choong Ang Vaccine Laboratories C
o., Ltd.
History for half a century,Front runner in the animal vaccine industry
Since established in 1968, Choong Ang Vaccine Laboratories Co., Ltd. (CAVAC) is an animal vaccine manufacturer which has pioneered the vaccine business and contributed to the rich lives of animals and humans by providing products and services beloved and trusted by customers.
In order to be the top tier in every business section, CAVAC is taking the lead in advancing the vaccine market in domestic and abroad by focusing on developing and training manufacturing-based technology, production management, human resources, investing R&D technology, empowering marketing, etc.
As a leading vaccine research/manufacturing company in the animal vaccine industry for half a century, CAVAC will always be with you for solutions that drives your business more insightful.
2019 Winning an award for the export of 10 million US dollars
2018 First Korean company of WHO GMP approval
2016 Egypt Governmental Audit
2013 Passed Bayer HealthCare audit
2009 Selected as one of Asia’s 200 Best Under A Billion companies by Forbes
2003 Listed in Korean Securities Dealers Automated Quotation (KOSDAQ)
1994 First Korean company of Korea Veterinary Good Manufacturing Practice (GMP) approval
1993 First Korean company of exporting its vaccines to the foreign countries (Thailand, Pakistan)
1968 Established Choong Ang Livestock Infectious Disease Laboratory
Your future is bright with CAVACCompany History
3Global Bio Leader - CAVAC
Innovative brandfor the best quality vaccine
CAVAC has developed and improved the quality of Korean vaccines on a par with the products of the world’s top companies.
CAVAC is always pursuing the perfection of animal disease prevention and management services by providing the nation’s best professional veterinary diagnostic service and technical support to farmers along with vaccines.
www.cavaclab.com Global Bio Leader - CAVAC4 5
Product list
Global Bio Leader - CAVAC 7
POULTRY VACCINES
Killed vaccines
Flu H9 ME+ND7 AIV (ME strain)+recombinant NDV (genotype VII) combined inactivated vaccine
500ml
Flu H9N2+ND AIV+NDV combined inactivated vaccineAvian influenza virus (AIV, H9N2) Newcastle disease virus (NDV, LaSota strain)
≥ 109.5EID50
≥ 109.5EID50
500ml
ND-7Recombinant NDV (genotype VII) inactivated vaccineNewcastle disease virus (NDV, rNDV-mF strain) ≥ 108.0EID50
500ml
Live vaccines
QX-IBQX type IBV live vaccine Infectious bronchitis virus (IBV, K40/09 HP strain) ≥ 102.5EID50
2,000 doses
QX-CastleIBV (QX type)+NDV combined live vaccine for day old chick at hatcheryInfectious bronchitis virus (IBV, K40/09 HP strain)Newcastle disease virus (NDV, NDRL0901 strain)
≥ 106.0EID50
≥ 102.5EID50
2,000 doses
IB-CastleIBV+NDV combined live vaccine for day old chick at hatcheryInfectious bronchitis virus (IBV, AVR1/08 strain) Newcastle disease virus (NDV, NDRL0901 strain)
≥ 102.5EID50
≥ 106.0EID50
2,000 doses
B1+IBNDV (B1)+IBV (H120) combined live vaccineNewcastle disease virus (NDV, B1 strain) Infectious bronchitis virus (IBV, H120 strain)
≥ 106.0EID50
≥ 102.5EID50
2,000 doses
LaSota+IBNDV (LaSota)+IBV (H120) combined live vaccineNewcastle disease virus (NDV, LaSota strain) Infectious bronchitis virus (IBV, H120 strain)
≥ 106.0EID50
≥ 102.5EID50
2,000 doses
LaSotaNDV (LaSota) live vaccineNewcastle disease virus (NDV, LaSota strain) ≥ 106.0EID50
2,000 doses
ND-0901NDV live vaccineNewcastle disease virus (NDV, NDRL0901 strain) ≥ 106.0EID50
2,000 doses
IBD Win+ IBDV live vaccine (Intermediate plus)Infectious bursal disease virus (IBDV, Winterfield 2512 strain) ≥ 102.0EID50
2,000 doses
GumboroIBDV live vaccine (Intermediate)Infectious bursal disease virus (IBDV, LZD 228-JAC3 strain) ≥ 102.0TCID50
2,000 doses
S/9RSalmonella Gallinarum (9R) live vaccineSalmonella Gallinarum (SG, 9R strain) ≥ 2×107.0CFU
1,000 doses
MG-FMycoplasma gallisepticum (F) live vaccineMycoplasma gallisepticum (MG, F810 strain) ≥ 1×105.0CCU
1,000 doses
Product list Vaccination program
Killed vaccines
Qx ND-7
IBV (QX type)+recombinant NDV (genotype VII) combined inactivated vaccineInfectious bronchitis virus (IBV, ADL05258 strain)Newcastle disease virus (NDV, rNDV-mF strain)
≥ 106.0EID50
≥ 108.0EID50
500ml
Qx Flu-4
IBV (KM91, QX type)+NDV+AIV combined inactivated vaccineInfectious bronchitis virus (IBV, KM91 strain) Infectious bronchitis virus (IBV, ADL05258 strain) Newcastle disease virus (NDV, LaSota strain) Avian influenza virus (AIV, H9N2)
≥ 106.0EID50
≥ 106.0EID50
≥ 108.0EID50
≥ 108.0EID50
1,000 doses
Qx Flu-5
IBV (KM91, QX type)+NDV+EDSV+AIV combined inactivated vaccineInfectious bronchitis virus (IBV, KM91 strain) Infectious bronchitis virus (IBV, ADL05258 strain)Newcastle disease virus (NDV, LaSota strain) Egg drop syndrome virus (EDSV, K11 strain) Avian influenza virus (AIV, H9N2)
≥ 106.0EID50
≥ 106.0EID50
≥ 108.0EID50
≥ 105.5EID50
≥ 108.0EID50
1,000 doses
3BN
IBV (M41, KM91, QX type)+NDV combined inactivated vaccineInfectious bronchitis virus (IBV, M41 strain) Infectious bronchitis virus (IBV, KM91 strain) Infectious bronchitis virus (IBV, ADL05258 strain)Newcastle disease virus (NDV, LaSota strain)
≥ 105.6EID50
≥ 106.3EID50
≥ 106.3EID50
≥ 108.2EID50
1,000 doses
ING-Plus
IBV (M41, KM91)+NDV+IBDV combined inactivated vaccineInfectious bronchitis virus (IBV, M41 strain) Infectious bronchitis virus (IBV, KM91 strain) Newcastle disease virus (NDV, LaSota strain) Infectious bursal disease virus (IBDV, CAG strain)
≥ 105.8EID50
≥ 106.1EID50
≥ 108.4EID50
≥ 106.4TCID50
1,000 doses
BNE
IBV (M41)+NDV+EDSV combined inactivated vaccineInfectious bronchitis virus (IBV, M41 strain) Newcastle disease virus (NDV, LaSota strain) Egg drop syndrome virus (EDSV, K11 strain)
≥ 105.9EID50
≥ 108.4EID50
≥ 107.7EID50
1,000 doses
Coryza-PlusInfectious coryza inactivated vaccineAvibacterium paragallinarum serotype A Avibacterium paragallinarum serotype C
≥ 108.0CFU≥ 108.0CFU
1,000 doses
AdenoFowl adenovirus inactivated vaccineFowl adenovirus type 4 (FAdV-4, K4 strain) ≥ 107.0TCID50
1,000 doses
Autogenous vaccine Avian E.coli inactivated vaccine 1,000 doses
※ It is optional to use IBD vaccine according to the level of the maternally derived antibody and history of the chicken flock.
IB-Castle
22 days
Gumboro or
IBD Win+
24 days
MG-F
35 days
Adeno
21 days
IB-Castle
12 days
ING-Plus or
3BN
7 days
IB-Castle
One day
Gumboro or
IBD Win+
16 days
AE
85 days
AEP
75 days
QX Flu-4
60 days
S/9R
42 days
E. coliCoryza
90 days
Qx Flu-5
100 days
S/9R
110 days
IB-Castle
95 days
Layer
IB-Castleor
QX-Castle
One day
QX-IB
10 days
Gumboro or
IBD Win+ ND-0901
12 days
Broiler
※ Regular vaccination of IB-Castle at intervals of 1~2 month after starting egg-laying
BreederGumboro
orIBD Win+
24 days
MG-F
35 days
IB-Castle
50 days
IB-Castle
22 days
IB-Castle
12 days
ING-Plus or
3BN
7 days
IB-Castle
One day
Gumboro or
IBD Win+
16 days
Adeno
100 days
IB-Castle
105 days
E. coliCoryza
115 days
ING-Plus
125 days
Qx Flu-5
90 days
AEP
75 days
QX Flu-4
60 days
AE
80 days
Poultry Vaccines Global Bio Leader - CAVAC8 9
IB-Castleor
QX-Castle
One day
ING-Plus or
3BN
7 days
QX-IB
10 days
Gumboro or
IBD Win+
14 days
IB-Castle
20 days
Gumboro or
IBD Win+
24 days
QX-Castle
40 daysNative chicken
PoulShot® IB-Castle PoulShot® ND-0901 PoulShot® IB-Castle PoulShot® ND-0901
PoulShot® IB-Castle protects against respiratory and nepropathogeinc IBV
Ciliostasis between K-I IBV challenged groups
NDV (NDRL0901): The latest isolate, respiratory and enterotrophic virusIBV (AVR1/08): Strong immunity induction of respiratory system
KJW, Kr005: Korean pathogenic strain / Herts 33: International standard pathogenic strainMY3519: Malaysian pathogenic strain / VN5/2007: Vietnamese pathogenic strain
Ciliostasis between QX-IBV challenged groups
Indication An aid in the control and prevention of Newcastle disease and infectious bronchitis caused by NDV and IBV
Composition and quantity
Infectious bronchitis virus (IBV, AVR1/08 strain) Newcastle disease virus (NDV, NDRL0901 strain)
≥ 102.5EID50
≥ 106.0EID50
Administration and dosage
-1st Administer by spray: 1day of age-2nd Administer by spray or drinking water: at least 5 days of age
Indication An aid in the control and prevention of Newcastle disease caused by NDV
Composition and quantity Newcastle disease virus (NDV, NDRL0901 strain) ≥ 106.0EID50
Administration and dosage Spray, Drinking water, Eye drop
LIVE
LIV
E
GroupNo. of chicks
Vaccination Challenge
Age Vaccine Route Strain
G1 8 1dayPoulShot® IB-Castle
SprayAVR1/08 Parental strain
G2 8 1day K40/09 CE4
G3 10 1day - - AVR1/08 Parental strain
G4 10 1day - - K40/09 CE4
Poultry Vaccines Global Bio Leader - CAVAC10 11
Group Vaccination/Challenge
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
8
7
6
5
4
3
2
1
0Vaccinated group Challenge control Non-vaccinated control
Protectio
n rate
Virus titer in bursa(EID50/ml)
Avg of B:B ratio
Protection rate
100% 100%
20%
3.33 3.33
1.96
4.2
7.06
100%
95%
90%
85%
80%
75%
70%
65%
60%
55%
50%
5
4.5
4
3.5
3
2.5
2
1.5
1
0.5
0
Protection rate HI titer (log2)
KJW Herts33 Kr005 MY3519 VN5/2007
Pro
tect
ion
rat
e HI titer (lo
g2)
High defense against various pathogenic NDV
Sco
re
Sco
re
G1 upper
G3 upper
G1 middle
G3 middle
G1 lower
G3 lower
4
3
2
1
0G2
upperG4
upperG2
middleG4
middleG2
lowerG4
lower
4
3
2
1
0
CT
valu
e in
vert
edGroup Vaccination/Challenge
G1 Vacc/K-I C G3- / K-I C G2 Vacc/QX C G4- / QX C
0
10
20
30
40
50
CT
valu
e in
vert
ed
Group Vaccination/Challenge
G1 Vacc/K-I C G3- / K-I C G2 Vacc/QX C G4- / QX C
0
10
20
30
40
50
Sco
re
Sco
re
G1 upper
G3 upper
G1 middle
G3 middle
G1 lower
G3 lower
4
3
2
1
0G2
upperG4
upperG2
middleG4
middleG2
lowerG4
lower
4
3
2
1
0
CT
valu
e in
vert
ed
Group Vaccination/Challenge
G1 Vacc/K-I C G3- / K-I C G2 Vacc/QX C G4- / QX C
0
10
20
30
40
50
CT
valu
e in
vert
ed
Group Vaccination/Challenge
G1 Vacc/K-I C G3- / K-I C G2 Vacc/QX C G4- / QX C
0
10
20
30
40
50
Group Tracheal position
Group Tracheal position
Poultry Vaccines Global Bio Leader - CAVAC12 13
PoulShot® Gumboro PoulShot® IBD Win+
PoulShot® IBD Win+ shows great protection and safety in chicks
Since commercial chicks possessed maternally-derived antibody prior to vaccination, they did not show 100% seroconversion one week after vaccinationB:B ratio: Bursa weight(g)/Body weight(g)x1,000, If the B:B ratio has increased, it means that protection was not enough.
DPV: Days post vaccination DPC: Days post challenge
Indication An aid in the control and prevention of infectious bursal disease caused by IBDV
Composition and quantity Infectious bursal disease virus (IBDV, LZD 228-JAC3 strain) ≥ 102.0TCID50
Administration and dosage
Vaccinate by drinking water.
Age Water 1 day 2L
10 days 20L40 days 80L
Indication An aid in the control and prevention of infectious bursal disease caused by IBDV
Composition and quantity Infectious bursal disease virus (IBDV, Winterfield 2512 strain) ≥102.0EID50
Administration and dosage
Vaccinate by drinking water.For broilers, vaccinate between 7 and 14 days of age.For layers and breeders, vaccinate between 10~14 days of age, and as a supplement, vaccinate between 10~12 weeks of age.
LIVE
LIV
E
Group0 DPV 0 DPC 10 DPC
MortalitySN titer (GMT) AGID SN titer (GMT) AGID SN titer (GMT) AGID
Vaccinated/Challenged 1.2 0% 2,702 100% 2,964 100% 0%
Vaccinated-only 1.3 0% 2,580 100% 2,048 100% 0%
Challenged-only 1.3 0% 1 0% 3,251 100% 76%
Control 1.3 0% 1 0% 1 0% 0%
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
3,500
3,000
2,500
2,000
1,500
1,000
500
-0 WPV 1 WPV 2 WPV
100% 100% 100%
80%
10%
0% 0% 0%
3 WPV Vaccinated Control
891
208
1,663
3,104
37141
676
9
AG
ID p
osi
tive
rat
e
SN t
iter
(G
MT)
Vaccinated Control 0 WPV 1 WPV 2 WPV 3 WPV
PoulShot® Gumboro shows perfect protection against very Virulent IBDV challenge
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
0
1
2
3
4
5
6
7
8
Protectio
n rate
3.3 3.33
100%
Vaccinated/Challenged
7.06
1.9620%
Challenged-only
4.2
100%
Control
Virus titer in bursa (EID50/ml) B:B ratio on average Protection rateWPV: Weeks post vaccination WPV: Weeks post vaccination
Poultry Vaccines Global Bio Leader - CAVAC14 15
PoulShot® MG-F PoulShot® S/9R
Increase in Egg Production and Egg QualityQuick Onset of Immunity and incredible Protection
against virulent strain
In the microplate agglutination test, Salmonella Gallinarum (SG, 9R strain) is uesd as an antigen
* Not applicable, there is no death.** Chickens in control group survived an average of 7.8 days after challenge with virulent strain.
Indication An aid in the control and prevention of avian mycoplasmosis caused by Mycoplasma gallisepticum
Composition and quantity Mycoplasma gallisepticum (MG, F810 strain) ≥ 1×105.0CCU
Administration and dosage
Reconstitute the vaccine with the enclosed diluent and administer one eye drop- 1st vaccination: 6 weeks of age- 2nd vaccination: 3 weeks after 1st vaccination
Indication An aid in the control and prevention of fowl typhoid caused by Salmonella Gallinarum
Composition and quantity Salmonella Gallinarum (SG, 9R strain) ≥ 2x107.0CFU
Administration and dosage
Administer 0.2ml subcutaneously in the neck after dissolving the vaccine in the diluent.-1st vaccination: 6~8 weeks of age-2nd vaccination: at 12 weeks of after the first vaccination
LIVE
LIV
E
Group Mortality
Re-isolation rate
Dead Alive
Liver Spleen Liver Spleen
PoulShot® S/9R 0% NA* NA 0% 0%
Vaccine N 0% NA NA 0% 0%
Control 93.3%** 100% 100% 100% 100%
F strain 6/85 ts-11 Bacterin
Form Lyophilized Lyophilized Frozen Emulsion
Administration Eye drop Spray Eye drop IM, SC
Vaccination age (week) 1st: 6 weeks, 2nd: 9 weeks ≥ 6 weeks 6~24 weeks (at least 2 weeks) < 16 weeks
Persistence in the tracheal epithelium Excellent Good Good No
Serological monitoring Very good Slight (almost negative) Moderate (about 50% positive) Very good
Field strain replacement Excellent Unknown Good No
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
3,500
3,000
2,500
2,000
1,500
1,000
500
-0 WPV
WPV: Weeks post vaccination WPV: Weeks post vaccination
1 WPV 2 WPV
100% 100% 100%
80%
10%
0% 0% 0%
3 WPV
AGID(positive rate)Vaccinated group
AGID(positive rate)Control
0 WPV
1 WPV
2 WPV
3 WPV
Vaccinated group
SN titer(GMT)
Control
891
208
1,663
3,104
37141
676
9
Egg
pro
du
ctio
n
NS farm
Ab
no
rmal eg
g
Age (weeks)16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41
120%
100%
80%
60%
40%
20%
0%
4.5%
4.0%
3.5%
3.0%
2.5%
2.0%
1.5%
1.0%
0.5%
0.0%
Egg production (vaccinated)
Abnormal eggs (vaccinated)
Egg production (control)
Abnormal eggs (control)
Egg
pro
du
ctio
nKM farm
Ab
no
rmal eg
g
Age (weeks)16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41
120%
100%
80%
60%
40%
20%
0%
4.5%
4.0%
3.5%
3.0%
2.5%
2.0%
1.5%
1.0%
0.5%
0.0%
Egg production (vaccinated)
Abnormal eggs (vaccinated)
Egg production (control)
Abnormal eggs (control)
1200
1000
800
600
400
200
0
Once at 6~8 wks
0 WPV 3 WPV 0 WPV 3 WPV 0 WPV 3 WPV
TwiceOnce at 18~20 wks
PoulShot® S/9R Intervet SG9R
1200
1000
800
600
400
200
0
Once at 6~8 wks
0 WPV 3 WPV 0 WPV 3 WPV 0 WPV 3 WP2V
TwiceOnce at 18~20 wks
Mic
rop
late
ag
glu
tin
atio
n t
iter
PoulShot® S/9R Vaccine N
WPV: Weeks post vaccination WP2V: Weeks post 2nd vaccination
Poultry Vaccines Global Bio Leader - CAVAC16 17
PoulShot® ND-7 PoulShot® Qx ND-7 PoulShot® BNE
PoulShot® ND-7 and PoulShot® Qx ND-7 form high-titer when compared to the control group
PoulShot® ND-7 and PoulShot® Qx ND-7 are containing ≥ 75 PD50 units per dose
During the trial period, the control group was inoculated with IB and ND vaccine (live and killed vaccine) as per the farm’s vaccination program
Three Major Diseases are protected by One Vaccine that provides the Prolonged high-titer
Indication An aid in the control and prevention of Newcastle disease caused by NDV
Composition and quantity
Recombinant Newcastle disease virus (NDV, rNDV-mF strain, genotype VII) ≥ 108.0EID50
Indication An aid the control and prevention of Newcastle disease and infectious bronchitis infection caused by NDV and IBV
Composition and quantity
Recombinant Newcastle disease virus (NDV, rNDV-mF strain, genotype VII) Infectious bronchitis virus (IBV, ADL05258 strain)
≥ 108.0EID50
≥ 106.0EID50
Administration and dosage
- Chicken can be vaccinated from one-day-old onwards.- Administer 0.2ml to the chickens within 10 days of age, 0.5ml to the chickens at least 10 days of age
IndicationAn aid in the control and prevention of infectious bronchitis, Newcastle disease and egg production syndrome caused by IBV, NDV, and EDSV
Composition and quantity
Infectious bronchitis virus (IBV, M41 strain) Newcastle disease virus (NDV, LaSota strain) Egg drop syndrome virus (EDSV, K11 strain)
≥ 105.9EID50
≥ 108.4EID50
≥ 107.7EID50
Administration and dosage
Administer 0.5ml intramuscularly not later than 3 week before egg-laying
KILLEDKI
LLED
Control Control
0 WPV 4 WPV 8 WPV 12 WPV 16 WPV 20 WPV 0 WPV 4 WPV 8 WPV 12 WPV 16 WPV 20 WPV5
6
7
8
9
10
5
6
7
8
9
10
11
1
1.5
2
2.5
3
3.5
4
4.5
Neu
tral
izat
ion
ind
ex (
NI)
HI t
iter
(lo
g2)
NDV, rNDV-mF IBV, ADL05258
WPV: Weeks post vaccination WPV: Weeks post vaccination
10
9
8
7
6
5
4
3
2
1
0
HI t
iter
(lo
g2)
IBV EDSVNDV
4 WPV0 WPV 8 WPV 16 WPV 20 WPV12 WPV
Poultry Vaccines18
PoulShot® 3BN
Three different types of IBV are protected by One Vaccine that provides the Prolonged high-titer
Indication An aid in the control and prevention of Newcastle disease and infectious bronchitis caused by NDV and IBV
Composition and quantity
Infectious bronchitis virus (IBV, M41 strain, Respiratory type)Infectious bronchitis virus (IBV, KM91 strain, Nephropathogenic type)Infectious bronchitis virus (IBV, ADL05258 strain, Nephropathogenic type)Newcastle disease virus (NDV, LaSota strain)
≥ 105.6EID50
≥ 106.3EID50
≥ 106.3EID50
≥ 108.2EID50
Administration and dosage
Administer 0.5ml intramuscularly-1st vaccination: 8~12 weeks of age-2nd vaccination: not later than 3 weeks before egg-laying
KILLED
PoulShot® 3BN protects against Nephropathogenic and Respiratory type of IBV100% Protection against highly pathogenic NDV
Six-week-old SPF chickens were inoculated twice at two-week intervals and challenged with three IBV serotypes WPV: Weeks post vaccination
18
16
14
12
10
8
6
4
2
0
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
9
8
7
6
5
4
3
2
1
0
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
35
30
25
20
15
10
5
0
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
SN t
iter
Protectio
n rate
16 87.5%
75%
100%
8 87.5%
25%
100%
32
25%
100%100%
3BN inoculated Control
Protection test (M41) Protection test (KM91) Protection test (QX-like)100% 88% 100%
Global Bio Leader - CAVAC 19
PoulShot® ING-Plus
PoulShot® ING-Plus provides stable and high potency level for the four major strains
Indication An aid the control and prevention of Newcastle disease, infectious bronchitis and infectious bursal disease caused by NDV, IBV and IBDV
Composition and quantity
Infectious bronchitis virus (IBV, M41 strain)Infectious bronchitis virus (IBV, KM91 strain) Newcastle disease virus (NDV, LaSota strain) Infectious bursal disease virus (IBDV, CAG strain)
≥ 105.8EID50
≥ 106.1EID50
≥ 108.4EID50
≥ 106.4TCID50
Administration and dosage Administer 0.5ml intramuscularly not later than 3 week before egg-laying
KILL
ED
10
9
8
7
6
5
4
3
2
1
0
1,500
1,350
1,200
1,050
900
750
600
450
300
150
0
Vaccinated group Control group
10
9
8
7
6
5
4
3
2
1
0
1,500
1,350
1,200
1,050
900
750
600
450
300
150
0IBV, M41
strainControl
IBV, M41strain
ControlIBV, KM91
strain
ControlND
ControlIBD
SN titerH
I tit
er
HI t
iter
(lo
g2) SN
titer
IBV, KM91 strain
ND IBD
O WPV 3 WPV 40 WPV
4.3
8.0 8.1
6.2
4.4
5.7
8.58.8
40
1,290
1,448
7.1
IBV, M41
4.3
8.0
7.17.1
IBV, KM91
8.1
6.2
4.4
NDV
5.7
8.58.8
IBDV
40
1,290
1,448
0 WPV 3 WPV 40 WPV
KILLED
PoulShot® Qx Flu-5
IndicationAn aid in the control and prevention of Newcastle disease, infectious bronchitis, egg drop syndrome and low pathogenic avian influenza infection caused by NDV, IBV, EDSV and AIV
Composition and quantity
Infectious bronchitis virus (IBV, ADL05258 strain) Infectious bronchitis virus (IBV, KM91 strain) Newcastle disease virus (NDV, LaSota strain) Egg drop syndrome virus (EDSV, K11 strain) Avian influenza virus (AIV, H9N2)
≥ 106.0EID50
≥ 106.0EID50
≥ 108.0EID50
≥ 105.5EID50
≥ 108.0EID50
Administration and dosage
Administer 0.5ml intramuscularly-1st vaccination: 8~12 weeks of age-2nd vaccination: 14~18 weeks of age
Only one vaccine can control the major diseases at a time
Group Before vaccination 3 weeks post 2nd vaccination Control
NDV <1 8.2 ± 0.63* <1
EDSV <1 10.7 ± 0.82 <1
AIV <1 7.9 ± 0.74 <1
IBV, KM91 strain NT** 2.6 <1
IBV, ADL05258 strain NT 2.7 <1
* Average HI titer ± standard deviation** Not tested
Poultry Vaccines20 Global Bio Leader - CAVAC 21
PoulShot® Adeno
PoulShot® Adeno protects from the clinical signs and gross lesion against the challenge
Indication An aid in the control and prevention of fowl adenovirus infection caused by FAdV
Composition and quantity Fowl adenovirus type 4 (FAdV-4, K4 strain) ≥ 107.0TCID50
Administration and dosage
Administer 0.5ml intramuscularly from 6 weeks old to 4 weeks before egg-laying in breeder and layer
KILL
ED
0
2
4
6
8
10
SN t
iter
(lo
g2)
0 WPV 4 WPC 8 WPC 12 WPC 16 WPC 20 WPC
7.2
00
1
2
3
4
5
6
7
8
SN t
iter
(lo
g2)
0 010
0 0
80 80
100 100 100
010%20%30%40%50%60%70%80%90%100%
Clin
cal s
igns
Mor
talit
y
Hepa
titis
Hydr
oper
icar
dium
Viru
s det
ectio
n
Clin
cal s
igns
Mor
talit
y
Hepa
titis
Hydr
oper
icar
dium
Viru
s det
ectio
n
Vaccinated/Challenged Challenged-only
Para
meter
Challenged-onlyVaccineate/Challenged
Vaccinated Control
Stable and Durable Immunity
0
2
4
6
8
10
HI t
iter
(lo
g2)
NDV EDSV AIV
Neu
tral
izat
ion
In
dex
(N
I)
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
IBV, KM91 strain IBV, ADL05258 strain
13 WP2V5 WP2V1 WP2V4 WP1V0 WP1V 9 WP2V13 WP2V5 WP2V1 WP2V4 WP1V0 WP1V 9 WP2V
WP1V: Weeks post 1st vaccinationWP2V: Weeks post 2nd vaccination
0
2
4
6
8
10
SN t
iter
(lo
g2)
0 WPV 4 WPC 8 WPC 12 WPC 16 WPC 20 WPC
7.2
00
1
2
3
4
5
6
7
8
SN t
iter
(lo
g2)
0 010
0 0
80 80
100 100 100
010%20%30%40%50%60%70%80%90%100%
Clin
cal s
igns
Mor
talit
y
Hepa
titis
Hydr
oper
icar
dium
Viru
s det
ectio
n
Clin
cal s
igns
Mor
talit
y
Hepa
titis
Hydr
oper
icar
dium
Viru
s det
ectio
n
Vaccinated/Challenged Challenged-only
Para
meter
Challenged-onlyVaccineate/Challenged
Vaccinated Control
WPV: Weeks post vaccination WPC: Weeks post challenge
KILLED
PoulShot® Flu H9N2+ND
Induction of Rapid, High and Uniform Antibodies in a Single Vaccination
100% Defense against NDV challenge
PoulShot® Flu H9N2+ND has been sold in Korea more than 12 years!
PoulShot® Flu H9N2+ND has already been registered in Kuwait, Jordan, Iraq, etc.
Indication An aid in the control and prevention of low pathogenic avian influenza infection and Newcastle disease caused by AIV and NDV
Composition and quantity
Avian influenza virus (AIV, H9N2) Newcastle disease virus (NDV, LaSota strain)
≥ 109.5EID50
≥ 109.5EID50
Administration and dosage
- Chicken can be vaccinated from one-day-old onwards- Administer 0.2ml to the chickens within 10 days of age, 0.5ml to the chickens at least 10 days of age
Poultry Vaccines22 Poultry Vaccines 23
0 WPV 0 WPV3 WPV 3 WPV
AIV
4
0
1
2
3
5
6
7
8
9
HI t
iter
(lo
g2)
NDV
Flu H9N2+ND 01 Flu H9N2+ND 02 Flu H9N2+ND 03
Tailor-made AI+ND vaccine for Middle East
PoulShot®
Flu H9 ME+ND7
WPV: Weeks post vaccination
Poultry Vaccines24
Application and Cautions of Poultry Vaccines
APPLICATION AND CAUTIONS OF POULTRY VACCINES
EYE DROP
Following the instructions, dilute the vaccine with a diluent and administer single drop. Gently grab the chicken by head for a good position and drop the vaccines onto the eye that should be absorbing the drop at all for sure (make sure the chicken blinks a few time). If the vaccine is absorbed properly, color of the tongue shall be changed and if not, try it again.
DRINKING WATER
The vaccine should be dissolved in drinking water (20~24℃), and then supply the vaccine after restricting water supply for 2 hours at least. In hot weather, deal with a larger amount of water. For better effect, add skim milk powder as a stabilizer by 0.2%. Stop using antibiotics and disinfectant in order not to disturb any effect of the vaccines. Please make sure that the vaccine is absorbed properly. For hygiene reasons, always wear gloves.
Global Bio Leader - CAVAC 25
Poultry Vaccines
Poultry Vaccines26 Global Bio Leader - CAVAC 27
Anatomical structure and Scab formation Anatomical structure of wing 4 days after vaccination 11 days after vaccination
Application and Cautions of Poultry Vaccines
SPRAY SUBCUTANEOUS INJECTION
WING WEB PUNCTURE
Vaccines are diluted with distilled water or clean water and administered by spraying from height of 50cm in order to administer in the eye and nasal cavity. The droplet size of spray should follow the administrations for use of each vaccine. The droplet size is generally 80~150µm and droplet size and spray method can be changed depending on age and construction of the farm. Before the vaccination, minimize ventilation if possible and dim the lights as low as possible to keep the chickens calm during the vaccination.
Preheat the vaccine that stored in the refrigerator over room temperature before use. Grasp the chicken by hoisting the skin with fingers to create a pocket between neck muscles and skin. Insert the needle at a 90˚ angle into the pocket of skin you made. Make sure that all of the vaccine gets injected and that the needle does not come out of the other side of the skin fold. Avoid injecting vaccine into the neck muscles, intradermaly or too close to the head of chicken. If you inject the vaccine correctly, you should notice a small bubble forming in the vaccination site.
Pull the chicken’s wing, and then the vaccine is put on the puncture niddle to inoculate the center of wing’s arachnoid triangle. Chicken’s vein, bones, wing nerve, and any other part of the body should be avoided. If you accidentally hurt the blood vessel, please do hemostasis and administrate it correctly. After 7~10 days of vaccination, check whether the scab is generated at the inoculation site.
INTRAMUSCULAR INJECTION
Inject vaccine following the administration for use and make sure the vaccine goes into the bird’s muscle. In the breast injection (left), the needle should be directed caudally at a 45˚ angle to the body. This will help avoid injecting the vaccine into the abdominal cavity or liver. When using the leg muscle for vaccination (right), the injection site should be made in the lateral side of the gastrocnemius muscle. Avoid major vessels, nerve, joints and the bone. After vaccination, please check failure of vaccination.
Spray
SprayVaccine
Distilled or clean water Dissolve the
vaccineCheck the
droplet size
Global Bio Leader - CAVAC 29
COMPANIONANIMAL
VACCINES
CaniShot® DHPPLComposition CaniShot® DHPP
Canine distemper virus (CDV, Onderstepoort strain) Canine adenovirus type 2 (CAV-2, Manhattan strain) Canine parvovirus (CPV, 780916-LP strain)Canine parainfluenza virus (CPIV, D008 strain) CaniShot® LeptoLeptospira canicolaLeptospira icterohaemorhhage
30%10%20%20%
0.5ml0.5ml
Indication An aid in the control and prevention of canine distemper, infectious canine hepatitis, parvovirus infection, infectious tracheobronchitis, and leptospirosis
Packaging unit DHPP-1 dose × 10, Lepto-1 dose × 10
CaniShot® RV-KIndication An aid in the control and prevention of rabies virus infection in dogs, cats, and cow
Packaging unit 1 dose × 10
Composition Rabies virus (RV, Pasteur strain) ≥107.0FAID50
CaniShot® CV Indication An aid in the control and prevention of coronavirus infection
Composition Canine coronavirus (CCV, K378 strain)
Packaging unit 1 dose × 20
≥106.0TCID50
CaniShot® PCIndication An aid in the control and prevention of parvovirus and coronavirus infection
Packaging unit 1 dose × 10
Composition Canine parvovirus (CPV, 780916-LP strain) Canine coronavirus (CCV, K378 strain)
≥105.0TCID50
≥104.0TCID50
CaniShot® K5Indication An aid in the control and prevention of canine distemper, infectious canine hepatitis,
parvovirus infection, and infectious tracheobronchitis
Packaging unit 1 dose × 10
Composition Canine distemper virus (CDV, Rockborn strain) Canine adenovirus type 2 (CAV-2, Manhattan strain) Canine parvovirus (CPV, 780916-LP strain) Canine parainfluenza virus (CPIV, D008 strain)
≥103.5TCID50
≥103.0TCID50
≥105.0TCID50
≥104.0TCID50
Product list
FeliShot® PHC An aid in the control and prevention of feline panleukopenia, feline viral rhinotracheitis and feline calicivirus infection in cats
Feline Panleukopenia virus (FPV, CU4 strain)Feline Herpesvirus (FHV, FVR-Goldstein strain)Feline Calicivirus (FCV, FCV-255 strain)
1 dose × 10
≥ 104.8TCID50
≥ 106.2TCID50
≥ 106.2TCID50
Indication
Composition
Packaging unit
RabbiShot® VHD Plus
An aid in the control and prevention of rabbit hemorrhagic disease in rabbits
Rabbit hemorhhagic diease virus VP60 protein
10 doses / 10ml
≥ 5,000 HAU
Indication
Composition
Packaging unit
Vaccination program
General vaccination program
Rabies vaccine program
Enforced program to prevent Parvovirus
PHC
8 weeks
PHC
14 weeks
PHC
11 weeks Annual booster vaccination
VHD Plus
2 months
VHD Plus
4 months Annual booster vaccination
KC-Plus
5 weeks
KC-Plus
7 weeks
DHPPLorK5
6 weeks
DHPPLorK5
8 weeks
DHPPLorK5
10 weeks
DHPPLorK5
12 weeks
Annual booster
vaccination
DHPPLorK5
PC
4 weeks
PC
8 weeks
DHPPLorK5
6 weeks
DHPPLorK5
10 weeks
DHPPLorK5
12 weeks
At the age older than 3 months
First
RV-K
Annual booster vaccination
Companion Animal Vaccines30 Global Bio Leader - CAVAC 31
Product list
CaniShot® KC-Plus An aid in the control and prevention of Kennel cough
Bordetella bronchiseptica (S-55 strain) Canine parainfluenza virus (CPIV, D008 strain)
1 dose × 10
≥ 2.0X108.0CFU≥ 104.0HAD50
Indication
Composition
Packaging unit
BOVINE VACCINES
Global Bio Leader - CAVAC 33
Product list
BoviShot® EphemerIndication
Composition
Packaging unit
An aid in the control and prevention of bovine ephemeral fever caused by BEFV
Bovine ephemeral fever virus (BEFV, BG strain)
5 doses / 10ml
≥ 103.0TCID50
BoviShot® RIDIndication An aid in the control and prevention of infectious bovine rhinotracheitis, bovine viral
diarrhea, and bovine parainfluenza virus infection caused by BHV-1, BVDV and BPIV-3
Packaging unit 2 doses / 10ml
Composition Bovine herpesvirus type 1 Bovine viral diarrhea virus Bovine parainfluenza virus type 3
30%30%30%
BoviShot® ROCOIndication
Composition
Packaging unit
An aid in the control and prevention of bovine rotavirus infection and bovine coronavirus caused by BRV and BCV
Bovine rotavirus (678 strain) Bovine rotavirus (P44 strain) Bovine coronavirus (BC94 strain)
1 dose / 2ml
≥ 105.0TCID50
≥ 105.0TCID50
≥ 105.0TCID50
Indication
Composition
Packaging unit
An aid in the control and prevention of bruceollosis caused by Brucella abortus.
Brucella abortus (RB51 strain)
10 doses / 10ml
≥ 4X109.0CFUBoviShot® Brucel
BoviShot® Pneumoguard 4
Indication
Composition
Packaging unit
An aid in the control and prevention of respiratory disease caused by Pasteurella multocida and Mannheimia haemolytica
Pasteurella multocida type A bacterin Pasteurella multocida type A outer membrane proteinMannheimia haemolytica type A bacterin Mannheimia haemolytica type A leukotoxoid
1 dose / 2ml
≥ 2X109.0CFU200µg/ml≥ 2X109.0CFU10µg/ml
BoviShot® EC-P Indication
Packaging unit
An aid in the control and prevention of colibacillosis caused by Escherichia coli
1 dose / 2ml
Composition E.coli pili (K99, F41) 40%
BoviShot® AkabaneAn aid in the control and prevention of abortions, stillbirths and congenital defects caused by Akabane virus
Akabane virus
3 doses / 3ml
50%
Indication
Composition
Packaging unit
Product list
BoviShot® Anth-LegAn aid in the control and prevention of anthrax and blackleg caused by Bacillus anthracis and Clostridium chauvoei
Indication
10 doses / 20mlPackaging unit
Bacillus arthracis Clostridium chauvoei
47.5 ~ 48.5%47.5 ~ 48.5%
Composition
Bovine Vaccines34
ROCOEC-P
6 weeks
ROCOEC-P
4 weeks Farrowing
Cow
Farrowing
ROCOAdminister 4ml (2 doses)
by oral route before giving colostrum
EphemerRID
AkabaneVaccination twice with
2~4 weeks interval
4 monthsCalf
RID
September
Akabane RID
Anth-Leg
MarchSeasonal vaccine
Global NETWORKThe world is our business place and the future is our market.The world is our business place and the future is our market.On the road to the world-class, CAVAC goes hand in hand with On the road to the world-class, CAVAC goes hand in hand with global families from more than 20 countries.global families from more than 20 countries.
Global Bio Leader - CAVAC 35